Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGNX -- MacroGenics -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (30)	12/22/2014 8:55:53 PM
From: Biotech Jim	Respond to of 188

<Janssen will invest $75M in MacroGenics via the purchase of 1,923,077 shares of common stock at $39 per share and will be fully responsible for developing MGD011. It expects to submit an Investigational New Drug (IND) application to the FDA in 2015.> Turns out that JNJ could have bought my small amount of shares last week when I sold them around $30. Just goes to show you (ie me) that trading these hot immuno-oncology stocks can be bad for your profits. Darn nice preclinical deal for MGNX and could be a very good deal for JNJ. Should be good news for REGN with their bi-specific antibody program(s), but minimal value is being given to REGN preclinical and early stage clinical programs since they are an earnings driven and late stage clinical company. For anyone interested in the difficulties, challenges and novel bi-specific antibody strategies used by REGN, see: http://files.shareholder.com/downloads/REGN/0x0x663982/5C790DBE-8A61-4E4F-A74D-3C7E138DDDE4/NYC_Ab_Mtg_May13fnl.pdf Does anyone know at what concentration the MGNX bi-specific Ab induces T cell killing?